37445000 County of San Diego the Salk Institute For
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Message from the Chairman
Abstract1 6/01/09 8:36 Page 1 Abstract1 6/01/09 8:36 Page 2 MESSAGE FROM THE CHAIRMAN Recent years have been marked by unprecedented growth and development in the life sciences in areas such as gene sequencing, protein interactions and molecular biology. Research conducted during the last decade has resulted in important technological and conceptual advances, along with the development of treatments and early stage cures for diseases like cancer or neurodegenerative diseases. The full sequencing of the human genome, and of a growing number of other living organisms, has heralded a new era in molecular biology and genetics for human medicine. Although these discoveries have opened an unprecedented path toward medical advances, they have also revealed that organic, physiological and genetic mechanisms are far more complex than initially believed. I am therefore particularly honoured that such an impressive panel of scientists agreed to gather together at Ipsen’s new corporate headquarters to lecture on the challenging and exciting perspectives of medical innovation. Jean-Luc Bélingard, Chairman and CEO of the Ipsen Group Abstract1 6/01/09 8:36 Page 3 Professor at the Collège de France and the Institut Pasteur, he is a member of the French Académie des Sciences, the National Academy of Sciences US, the Institute of Medicine of the NAS. He discovered the allostery of proteins and isolated the nicotinic receptor of acetylcholine. Past president of the Comité National d’Ethique, he is the president of the Commission des dations, and the Jean-Pierre Changeux laureate of many scientific prizes: Chairperson médaille d’or du CNRS, Balzan prize, Louis-Jeantet Prize, Biotechnology Study Center of the New York University school of Medicine award, Jean-Louis Signoret Prize of la Fondation Ipsen, the National Academy of Sciences award in neurociences (2007). -
Dreams Hope Courage Reality Table of Contents
dreams hope courage reality Table of Contents 1. About Salk 14. Key Contacts 3. The Salk Difference 15. Financial Overview 4. Scientific Priorities 16. Salk Leadership 6. Discoveries 17. Board of Trustees 8. Salk Scientists 18. Salk Architecture 10. Salk by the Numbers 20. Get to Know Us 11. Why I Support Salk... 21. Our Mission 12. Supporting Discoveries About Salk Jonas Salk changed the world. Inspired to rid civilization of polio, he used basic science to solve its mysteries and in the process helped alter the course of the 20th century along with the future of science, medicine and human health. Untold millions have benefited from his work. The Salk Institute was created to attract the best scientific minds in the world. We’ve built on his vision and have become the leading center for independent research, delving into the most serious biological questions of our time. Experts come from around the globe to work in open collaboration—conducting innovative and daring research, mapping discoveries and developing the blueprints so that cures can happen, anywhere in the world. Twelve Nobel laureates have called the Salk Institute home. 1 It’s this “critical mass of intellect,” which embraces the most modern technologies and prizes discovery over credit, that distinguishes Salk. And it results in some of the world’s most breathtaking findings, which advance our understanding of cancer, aging and the brain. These are the first steps that will lead to tomorrow’s cures for cancer, Alzheimer’s, Parkinson’s, heart disease, metabolic diseases, ALS, schizophrenia, childhood development disorders and spinal cord injuries. -
EMBO Conference Takes to the Sea Life Sciences in Portugal
SUMMER 2013 ISSUE 24 encounters page 3 page 7 Life sciences in Portugal The limits of privacy page 8 EMBO Conference takes to the sea EDITORIAL Maria Leptin, Director of EMBO, INTERVIEW EMBO Associate Member Tom SPOTLIGHT Read about how the EMBO discusses the San Francisco Declaration Cech shares his views on science in Europe and Courses & Workshops Programme funds on Research Assessment and some of the describes some recent productive collisions. meetings for life scientists in Europe. concerns about Journal Impact Factors. PAGE 2 PAGE 5 PAGE 9 www.embo.org COMMENTARY INSIDE SCIENTIFIC PUBLISHING panels have to evaluate more than a hundred The San Francisco Declaration on applicants to establish a short list for in-depth assessment, they cannot be expected to form their views by reading the original publications Research Assessment of all of the applicants. I believe that the quality of the journal in More than 7000 scientists and 250 science organizations have by now put which research is published can, in principle, their names to a joint statement called the San Francisco Declaration on be used for assessment because it reflects how the expert community who is most competent Research Assessment (DORA; am.ascb.org/dora). The declaration calls to judge it views the science. There has always on the world’s scientific community to avoid misusing the Journal Impact been a prestige factor associated with the publi- Factor in evaluating research for funding, hiring, promotion, or institutional cation of papers in certain journals even before the impact factor existed. This prestige is in many effectiveness. -
Gene Therapy Salk’S Own ‘Extraordinary Measures’ Revives Hope for Human Treatment
INSIDE » Board Elects New Trustees » Martin Hetzer Receives Scholar Award » One on One with Bob Lizarraga Where cures begin. THE SALK INSTITUTE FOR BIOLOGICAL STUDIES 02 | 10 Gene Therapy Salk’s Own ‘Extraordinary Measures’ Revives Hope for Human Treatment ALSO IN THIS ISSUE » Sam Pfaff Receives $15.6M Grant » Researchers Map First Human Epigenome » Unlocking the Mechanisms to Limb Regeneration Inside » 2009 Donor Honor Roll February 2010 Inside Salk 4 12 Three sisters help two terminally ill boys. One on One with Bob Lizarraga EXECUTIVE MESSAGE NEWS BRIEFS 3 Investing for the Long Term 22-23 Inder Verma Receives Spector Prize, Gates Foundation Grant COVER STORY Postdocs Honored with 4-11 Gene Therapy Fellowships from Salk’s Center Salk’s Own ‘Extraordinary for Nutritional Genomics Measures’ Revives Hope Fred H. Gage Elected to the For Human Treatment European Molecular Biology Organization INSTITUTE NEWS Clodagh O’Shea Receives One on One with … 12-21 Sontag Foundation’s Bob Lizarraga Distinguished Scientist Award William R. Brody, M.D., Ph.D. Glenn Center Scholars Program CIRM Awards Samuel L. Pfaff President Opens Door to Sharing of Ideas $15.6 Million to Develop Marsha A. Chandler, Ph.D. Stem Cell-Based ALS Therapy Executive Vice President Salk Prepares to Build on Rebecca Newman Annual Tax Seminar’s Success Martin HetzerWins 2009 Vice President, Aging Research Award Development and Communications Salk Institute Board of Susan Trebach Trustees Elects Leaders in Senior Director, Venture Capital and Publishing Communications CALENDAR to its Membership Back Cover Mauricio Minotta Director, Communications Discovery Roundup Editor, Inside Salk Gina Kirchweger Director, Scientific Communications Sarah Loffler Design and Production Coordinator Joe Belcovson and Kent Schnoeker Staff Photographers studio L. -
RECOMBINANT DNA ADVISORY COMMITTEE Minutes of Meeting December 15-16, 1997
RECOMBINANT DNA ADVISORY COMMITTEE Minutes of Meeting December 15-16, 1997 U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES Public Health Service National Institutes of Health TABLE OF CONTENTS I. Call to Order and Opening Remarks/Mickelson II. RAC Forum on New Technologies III. Food and Drug Administration (FDA) Presentation: Discussion of the Risks of Gonadal Distribution and Inadvertent Germ Line Integration in Patients Receiving Direct Administration of Gene Therapy Vectors IV. Call to Order/Mickelson V. Minutes of the September 12, 1997, Meeting/Ando, Greenblatt VI. Update on Data Management/Greenblatt VII. Amendment to Institutional Biosafety Committee Approvals of Experiments Involving Transgenic Rodents Under Section III of the NIH Guidelines/Aguilar-Cordova VIII. Amendment to Appendix K, Physical Containment for Large Scale Uses of Organisms Containing Recombinant DNA Molecules/McGarrity IX. Amendment to Section III-D-6, Experiments Involving More than 10 Liters of Culture/Knazek X. Human Gene Transfer Protocol #9708-209 entitled: Systemic and Respiratory Immune Response to Administration of an Adenovirus Type 5 Gene Transfer Vector (AdGVCD.10)/Harvey, Crystal XI. Human Gene Transfer Protocol #9711-221 entitled: Phase I Study of Direct Administration of a Replication-Deficient Adenovirus Vector (AdGVVEGF121.10) Containing the VEGF121 cDNA to the Ischemic Myocardium of Individuals with Life Threatening Diffuse Coronary Artery Disease/Crystal XII. Amendment to Appendix M-I, Submission Requirements--Human Gene Transfer Experiments Regarding the Timing of Institutional Biosafety Committee and Institutional Review Board Page 1 Approvals/Markert XIII. Human Gene Transfer Protocol #9708-211 entitled: Gene Therapy for Canavan Disease/Seashore XIV. Amendment to Appendix M-I, Submission Requirements--Human Gene Transfer Experiments Regarding Deadline Submission for RAC Review/McIvor XV. -
04 | 10 April 2010 Inside Salk
Where cures begin. THE SALK INSTITUTE FOR BIOLOGICAL STUDIES 04 | 10 April 2010 Inside Salk 15 16 Chihuly at the Salk One-on-One with Joe EXECUTIVE MESSAGE PHILANTHROPY 3 Salk’s History: A Story Rich 25 Ballroom Dancer Gives Back in Creativity and Scientific to Basic Research Discoveries Broadway, Film Star Liza Minnelli to Perform on COVER STORY Symphony at Salk Stage 4-13 Celebrating 50 Years of Scientific Discovery– NEWS BRIEFS The Salk Way 26-27 MIT and Stanford Scientists Join Salk Institute’s William R. Brody, M.D., Ph.D. 14-22 INSTITUTE NEWS Non-Resident Fellows President Breaking Ground for Marsha A. Chandler, Ph.D. 14 Institute Receives $4.4M Ground-Breaking Facility Executive Vice President NIH Recovery Act Grant for Rebecca Newman New Data Center Vice President, 15 Institute Kicks Off Development and Communications 50th Anniversary Celebration Inder Verma to Receive Susan Trebach with Chihuly at the Salk Pasarow Award for Cancer Senior Director, Research Communications 16 One-on-One with… Joe Ecker Mauricio Minotta Early-Career Scientists Director, Communications Cancer Researcher Tony Hunter Receive Developmental Chairs Editor, Inside Salk 18 Named to Frederick W. and Gina Kirchweger Joanna J. Mitchell Chair Jonas Salk Focus of Director, Israel’s Owl Competition Scientific Communications 19 International Journalists Tour Sarah Loffler Neuroscience Labs at Salk Design and Production Coordinator CALENDAR Liz Hincks 20 Risk Taking Leads Back Cover Web Editor James Fitzpatrick to Photography: High-Resolution World of Joe Belcovson, Marc Lieberman, Biophotonics Darrel K. Miller, Kent Schnoeker Kat Kearney 21 Former Institute Lab Tech Circulation Manager Julia Miller Returns as studio L. -
Breakthrough Research Life Sciences in India Public and Private Health
WINTER 2013|2014 ISSUE 26 encounters Public Michael Hall and private health PAGE 3 PAGE 6 Breakthrough Paul Flicek research BEAUTY 17 E PAG PAGES 4 – 5 SUBMERGED Life sciences in India ©Eric | www.kahikaiimages.com Röttinger Editorial Maria Leptin introduces the Feature Alexander Levitzki describes the Interviews Young Investigators and 50th anniversary year of EMBO. evolution of targeted cancer treatments. Installation Grantees discuss their research, careers and challenges. PAGE 2 PAGE 7 PAGES 8 – 9 www.embo.org EMBO 50TH ANNIVERSARY years of 50achievement Director’s welcome to the 50th anniversary of EMBO 2014 is the 50th anniversary of EMBO and it is a pleasure to inform you about our plans for celebration.When I became Director in 2010, I was familiar with some of the remarkable work of EMBO since I had served on committees responsible for the membership and publications. Since then, my appreciation has deepened further by working more closely with its community of scientists and staff. We can be proud of what EMBO has achieved. Since 1964, EMBO has created, developed and nurtured a network of some of the best life scientists who have helped to build a successful European research environment. Over the course of 2014, we have planned activi- available via the timeline on our web site and the growth of a scientific community in Europe. It is ties and events to highlight the many contribu- book will be published by April this year. These the spirit of this community that we hope to cap- tions that EMBO has made to the life sciences. -
Inder Verma, Ph.D. Lentiviral Vectors
© 1999 Nature America Inc. • http://biotech.nature.com Speakers • Inder Verma, Ph.D. Lentiviral Vectors Professor The “bottleneck” of current gene therapy approaches is the lack The Salk Institute of an efficient gene delivery system. Retroviral vectors have Laboratory of Genetics been very useful for ex vivo gene delivery, but suffer two major 10010 North Torrey Pines Blvd. La Jolla, CA 92186 limitations: (1) inability to infect post-mitotic cells, and (2) fol- United States lowing implantation of the transduced cells, the expression of the transgene is “shut off”. The adenoviral vectors can be gen- erated at high titers (>1011-1012 pfu/ml) but also have two major limitations: (1) Generation of CTLs to viral proteins, and (2) humoral response to viral proteins precluding repeat infection. 1964-1966 M.Sc. Biochemistry, Lucknow University, India The adeno-associated viral (AAV) vectors have not been 1967-1971 Ph.D. Biochemistry, The Weizmann Institute of Science, exploited extensively partly due to inability to generate high Rehovot, Israel titer helper free recombinant viruses. Furthermore, the size of 1971-1974 Postdoctoral Fellow, Department of Biology, the transgene that can be accommodated to generate viable vec- Massachusetts Institute of Technology, Cambridge, MA tors is limited. (with D. Baltimore) 1974-1979 Assistant Professor, The Salk Institute, La Jolla, CA To overcome some of these difficulties we have con- 1979-1983 Associate Professor, The Salk Institute structed lentiviral vectors based on HIV and pseudotyping with 1979-1983 Adjunct Associate Professor, Department of Biology, VSVG protein. We show that high titer helper free recombinant University of California, San Diego HIV vectors (~108-109 CFU/ml) can be generated which can 1983-1985 Senior Member, Molecular Biology and Virology Laboratory, The Salk Institute infect non-dividing cells in vitro. -
RENATO DULBECCO Celebrare Una Leggenda
INSIDE »» WRecord-settingaitt Advanced Biophotonicsyear for fundraising Center Grand» SDG&E Opening names » One Salk on Energy One with…Thomas Champion Albright» New drug target for lung cancer Where cures begin. THE SALK INSTITUTE FOR BIOLOGICAL STUDIES 07 | 12 RENATO DULBECCO celebrare una leggenda REMEMBERING Wylie July 2012 Inside Salk 4 24 Renato Dulbecco: A Giant of Cancer Biology Next generation: Carol Marchetto 3 EXECUTIVE MESSAGE 21 A new drug target for lung cancer Salk scientists use an old theory to discover LEAD STORY new targets in the fight against breast cancer William R. Brody, M.D., Ph.D. 4 Renato Dulbecco: A Giant of Cancer Biology President 22 Salk scientists discover how plants grow to Marsha A. Chandler, Ph.D. INSTITUTE NEWS escape shade Executive Vice President 11 Salk scientists honored with endowed chairs Sending out an SOS: How telomeres incriminate Rebecca Newman 12 Elizabeth Blackburn awarded 2012 American cells that can’t divide Vice President, Institute of Chemists Gold Medal Development and Communications 23 Discovery of extremely long-lived proteins Stacie Spector The Salk Institute welcomes new may provide insight to cell aging and Chief Communications Officer Non-Resident Fellow neurodegenerative diseases Andy Hoang 13 A record-setting year for fundraising Director, Media Relations NEXT GENERATION 24 The next generation: Carol Marchetto Christopher Emery Faculty members receive promotions A passion for the lab bench—and beyond Director, Scientific Communications 14 A license to heal Sarah Lifton 26 Science -
Social Influence Given (Partially) Deliberate Matching: Career Imprints in the Creation of Academic Entrepreneurs
Social Influence Given (Partially) Deliberate Matching: Career Imprints in the Creation of Academic Entrepreneurs The MIT Faculty has made this article openly available. Please share how this access benefits you. Your story matters. Citation Azoulay, Pierre et al. “Social Influence Given (Partially) Deliberate Matching: Career Imprints in the Creation of Academic Entrepreneurs.” American Journal of Sociology 122, 4 (January 2017): 1223–1271 © 2017 University of Chicago As Published http://dx.doi.org/10.1086/689890 Publisher University of Chicago Press Version Final published version Citable link http://hdl.handle.net/1721.1/113218 Terms of Use Article is made available in accordance with the publisher's policy and may be subject to US copyright law. Please refer to the publisher's site for terms of use. Social Influence Given (Partially) Deliberate Matching: Career Imprints in the Creation of Academic Entrepreneurs1 Pierre Azoulay Toby E. Stuart Massachusetts Institute University of California, Berkeley of Technology Christopher C. Liu University of Toronto Actors and associates often match on a few dimensions that matter most for the relationship at hand. In so doing, they are exposed to un- anticipated social influences because counterparts have broader atti- tudes and preferences than would-be contacts considered when they first chose to pair. The authors label as “partially deliberate” social matching that occurs on a small set of attributes, and they present em- pirical methods for identifying causal social influence effects when re- lationships follow this generative logic. A data set tracking the train- ing and professional activities of academic biomedical scientists is used to show that young scientists adopt their advisers’ orientations toward commercial science as evidenced by adviser-to-advisee trans- mission of patenting behavior. -
NAS/NAM (Chair); Columbia University Dr. Mary J
- Committee's CURRENT MEMBERSHIP follows - Dr. Martin Chalfie*; NAS/NAM (Chair); Columbia University Dr. Mary Jane West-Eberhard; NAS (Vice Chair); Smithsonian Tropical Research Institute Dr. Chris Beyrer; NAM; Johns Hopkins Bloomberg School of Public Health Dr. John Carlson; NAS; Yale University Dr. Christine K. Cassel; NAM; University of California, San Francisco Dr. M. T. Clegg; NAS; University of California, Irvine Dr. Carlos del Rio; NAM (Ex Official Member); National Academy of Medicine Dr. Vanessa Northington Gamble; NAM; The George Washington University Dr. John G. Hildebrand; NAS (Ex Officio Member); National Academy of Sciences Dr. John G. Kassakian; NAE; Massachusetts Institute of Technology Dr. Michael Katz; NAM; Columbia University/Stanford University Dr. Anthony Leggett*; NAS; University of Illinois at Urbana-Champaign Dr. Elaine S. Oran; NAE; Texas A&M University Dr. Elsa Reichmanis; NAE; Georgia Institute of Technology Dr. James Tien; NAE (Ex Officio Member); National Academy of Engineering - Committee's FORMER CHAIRS follow– Dr. Robert W. Kates; NAS (Chair, 1976-1979); University of Maine Dr. Lipman Bers; NAS (Chair, 1979-1984); Columbia University Dr. Eliot Stellar; NAS/NAM (Chair, 1984-1993); University of Pennsylvania Dr. Torsten N. Wiesel*; NAS/NAM (Chair, 1994-2004); The Rockefeller University Dr. Peter C. Agre*; NAS/NAM (Chair, 2005-2007); Johns Hopkins Bloomberg School of Public Health Dr. Sidney Verba; NAS (Chair, 2008-2014); Harvard University *Nobel Laureate - Committee's PAST MEMBERSHIP follows (Sorted By Last Name) – Dr. Andreas Acrivos; NAS/NAE; The City College of the City University of New York Dr. Peter C. Agre*; NAS/NAM (Former Chair); Johns Hopkins Bloomberg School of Public Health Dr. -
HIV Causes AIDS. to Argue Otherwise Costs Lives
HIV causes AIDS. To argue otherwise costs lives. As scientists and clinicians concerned about the HIV/AIDS pandemic, we have purchased this advertising space to counter the fallacious arguments of a few colleagues who claim that the cause of AIDS is in doubt. There is no such scientific controversy. The cause of AIDS is as well established as the causes of polio, measles, influenza, or any other viral disease. HIV infection correlates with AIDS. More than 95% of people infected with HIV die of AIDS within 15 years after infection, unless they are treated. The AIDS epidemic in people — men, women, children — is associated only with HIV infection. AIDS is not uniformly associated with membership in any particular “risk” group. Early in the epidemic, recipients of blood products, especially people with hemophilia, were at high risk of AIDS. Where HIV has been eliminated from the blood supply, new cases of transfusion-associated AIDS have not occurred. Furthermore, in countries where rates of HIV infection have increased, AIDS deaths have risen along with cases of AIDS. Similar viruses cause AIDS in animals. A virus very similar to HIV, SIV, causes AIDS in rhesus monkeys. Pure SIV DNA can initiate infection leading to AIDS, excluding any other possible causes for the disease in monkeys. Treatment of HIV infection treats AIDS. If patients sick with AIDS are treated with drugs that greatly reduce the amount of HIV in their blood, their health can improve dramatically, and they often return to normal, productive lives. Such drugs also prevent or delay the onset of AIDS.